The latest news from Arcinova
Arcinova Releases Latest Case StudyThe challenge - to develop stable sterile formulations of a drug substance for intravenous administration in phase I clinical trials. The drug substance, intended for the treatment of CNS (C
Arcinova Festive FundraisingThis year we filled shoeboxes for the amazing Destiny Streetworx charity, filling 23 boxes in total and sending bags of hand knitted hats and scarves to support the homeless people of the North Ea
Arcinova hosts Guinness World Record Holder for STEM Christmas LectureWe were proud to invite over 150 local schoolchildren to attend a STEM Ambassador Hub North East Christmas Lecture at our facility this month. The event gave pupils from across North Northumberlan
The expertise of the next generation and the implementation of flow chemistry in pharmaOur Head of Drug Substance, Paul Quigley, shared his insights into how the next generation of scientists are using their skills and knowledge to help bridge the gap in expertise between batch and
Ian Shott provides foreword to the ‘Engineering Biology: A Priority for Growth’ reportOur “Individuals, groups and communities working in engineering biology must get together at this important time and agree how they can build better connections and incentivise this collaboratio
WardHadaway Fastest50!We are delighted to have been included in the Ward Hadaway #Fastest50 growing companies in the #Northeast. A huge congratulations to all participating companies! See the full list
Arcinova Fundraising Sept/Oct 2019
Arcinova appoints new CEO to continue rapid expansion
Arcinova delighted to be finalists in OBN awards!
Discover how Arcinova can help
We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.